Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date

被引：26
|
作者：
Montemorano, Lauren [1 ]
Lightfoot, Michelle D. S. [2 ]
Bixel, Kristin [2 ]
机构：
[1] Ohio State Univ, Dept Obstet & Gynecol, Wexner Med Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, James Canc Hosp, Dept Obstet & Gynecol,Div Gynecol Oncol, Columbus, OH 43210 USA
来源：
ONCOTARGETS AND THERAPY | 2019年 / 12卷
关键词：
olaparib; PARP inhibitor; ovarian cancer; maintenance; DOUBLE-BLIND; THERAPY; CHEMOTHERAPY; BEVACIZUMAB; INHIBITORS; CARCINOMA;
D O I：
10.2147/OTT.S195552
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have received multiple prior lines of chemotherapy. In this review, we focus on the use of olaparib in the maintenance setting including the evidence to date, ongoing research, and future directions.
引用
收藏
页码：11497 / 11506
页数：10
相关论文
共 50 条
  • [41] Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
    Chen, Qian
    Li, Xiaoli
    Zhang, Zhen
    Wu, Tong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials
    Korkmaz, Taner
    Seber, Selcuk
    Basaran, Gul
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 98 : 180 - 188
  • [43] Update on PARP Inhibitors for the Treatment of Ovarian Cancer
    Liu, Joyce
    Matulonis, Ursula A.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2025, 23 (02) : 100 - 110
  • [44] Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial
    Sabatier, Renaud
    Rousseau, Frederique
    Joly, Florence
    Cropet, Claire
    Montegut, Coline
    Frindte, Johanna
    Cinieri, Saverio
    Alia, Eva M. Guerra
    Polterauer, Stephan
    Yoshida, Hiroyuki
    Vergote, Ignace
    Colombo, Nicoletta
    Hietanen, Sakari
    Largillier, Remi
    Canzler, Ulrich
    Gratet, Alain
    Marme, Frederik
    Favier, Laure
    Pujade-Lauraine, Eric
    Ray-Coquard, Isabelle
    EUROPEAN JOURNAL OF CANCER, 2023, 181 : 42 - 52
  • [45] Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib
    Shaw, Heather M.
    Hall, Marcia
    ONCOTARGETS AND THERAPY, 2013, 6 : 1197 - 1206
  • [46] Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
    Ledermann, Jonathan A.
    Harter, Philipp
    Gourley, Charlie
    Friedlander, Michael
    Vergote, Ignace
    Rustin, Gordon
    Scott, Clare
    Meier, Werner
    Shapira-Frommer, Ronnie
    Safra, Tamar
    Matei, Daniela
    Fielding, Anitra
    Bennett, Bryan
    Parry, David
    Spencer, Stuart
    Mann, Helen
    Matulonis, Ursula
    BRITISH JOURNAL OF CANCER, 2016, 115 (11) : 1313 - 1320
  • [47] Is It Time to Reassess the Role of Radiotherapy Treatment in Ovarian Cancer?
    Macchia, Gabriella
    Titone, Francesca
    Restaino, Stefano
    Arcieri, Martina
    Pellecchia, Giulia
    Andreetta, Claudia
    Driul, Lorenza
    Vizzielli, Giuseppe
    Pezzulla, Donato
    HEALTHCARE, 2023, 11 (17)
  • [48] MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer
    Yi, Jingyan
    Liu, Chongya
    Tao, Zhiwei
    Wang, Min
    Jia, Yaxun
    Sang, Xiaolin
    Shen, Lanlin
    Xue, Yijue
    Jiang, Kui
    Luo, Fuwen
    Liu, Pixu
    Cheng, Hailing
    EBIOMEDICINE, 2019, 43 : 225 - 237
  • [49] Olaparib maintenance therapy for platinum-sensitive relapsed ovarian cancer at a single institution: A retrospective study
    Katsuda, Takahiro
    Nishio, Shin
    Tasaki, Shingo
    Park, Jongmyung
    Tasaki, Kazuto
    Tsuda, Naotake
    Ushijima, Kimio
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2024, 50 (07) : 1192 - 1200
  • [50] Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer
    Elayapillai, Suganthapriya
    Ramraj, Satishkumar
    Benbrook, Doris Mangiaracina
    Bieniasz, Magdalena
    Wang, Lin
    Pathuri, Gopal
    Isingizwe, Zitha Redempta
    Kennedy, Amy L.
    Zhao, Yan D.
    Lightfoot, Stanley
    Hunsucker, Lauri A.
    Gunderson, Camille C.
    GYNECOLOGIC ONCOLOGY, 2021, 160 (01) : 302 - 311
12345